Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2013

01-05-2013 | Original Article

Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer

Authors: Alexander W. Sauter, Daniel Spira, Maximilian Schulze, Christina Pfannenberg, Jürgen Hetzel, Matthias Reimold, Ernst Klotz, Claus D. Claussen, Marius S. Horger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2013

Login to get access

Abstract

Purpose

The aim of this study was to investigate correlations between glucose metabolism as determined by [18F]FDG PET/CT and tumour perfusion as quantified by volume perfusion CT in primary tumours and mediastinal lymph nodes (MLN) of patients with non-small-cell lung cancer (NSCLC).

Methods

Enrolled in the study were 17 patients with NSCLC. [18F]FDG uptake was quantified in terms of SUVmax and SUVavg. Blood flow (BF), blood volume (BV) and flow extraction product (Ktrans) were determined as perfusion parameters. The correlations between the perfusion parameters and [18F]FDG uptake values were subsequently evaluated.

Results

For the primary tumours, no correlations were found between perfusion parameters and [18F]FDG uptake. In MLN, there were negative correlations between BF and SUVavg (r = −0.383), BV and SUVavg (r = −0.406), and BV and SUVmax (r = −0.377), but not between BF and SUVmax, Ktrans and SUVavg, or Ktrans and SUVmax. Additionally, in MLN with SUVmax >2.5 there were negative correlations between BF and SUVavg (r = −0.510), BV and SUVavg (r = −0.390), BF and SUVmax (r = −0.536), as well as BV and SUVmax (r = −0.346).

Conclusion

Perfusion and glucose metabolism seemed to be uncoupled in large primary tumours, but an inverse correlation was observed in MLN. This information may help improve therapy planning and response evaluation.
Literature
1.
2.
Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193–9.PubMedCrossRef
3.
Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol. 2005;23:3257–69.PubMedCrossRef
4.
Walker CM, Chung JH, Abbott GF, Little BP, El-Sherief AH, Shepard JA, et al. Mediastinal lymph node staging: from noninvasive to surgical. AJR Am J Roentgenol. 2012;199:W54–64.PubMedCrossRef
5.
Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178S–201.PubMedCrossRef
6.
Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, De Wever WF, Verbeken EK, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med. 1998;25:1495–501.PubMedCrossRef
7.
Schmid-Bindert G, Henzler T, Chu TQ, Meyer M, Nance Jr JW, Schoepf UJ, et al. Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Eur Radiol. 2012;22:93–103.PubMedCrossRef
8.
Mandeville HC, Ng QS, Daley FM, Barber PR, Pierce G, Finch J, et al. Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia. Radiology. 2012;264:581–9.PubMedCrossRef
9.
de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med. 2011;52:48–55.PubMedCrossRef
10.
Schillaci O, Spanu A, Scopinaro F, Monteleone F, Solinas ME, Volpino P, et al. Mediastinal lymph node involvement in non-small cell lung cancer: evaluation with 99mTc-tetrofosmin SPECT and comparison with CT. J Nucl Med. 2003;44:1219–24.PubMed
11.
Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res. 2002;8:2109–15.PubMed
12.
Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:156–63.PubMedCrossRef
13.
Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507–14.PubMedCrossRef
14.
Bollineni VR, Wiegman EM, Pruim J, Groen HJ, Langendijk JA. Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat Rev. 2012;38:1027–32.PubMedCrossRef
15.
Veronesi G, Landoni C, Pelosi G, Picchio M, Sonzogni A, Leon ME, et al. Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases. Br J Cancer. 2002;86:1391–5.PubMedCrossRef
16.
Hirasawa S, Tsushima Y, Takei H, Hirasawa H, Taketomi-Takahashi A, Takano A, et al. Inverse correlation between tumor perfusion and glucose uptake in human head and neck tumors. Acad Radiol. 2007;14:312–8.PubMedCrossRef
17.
Ohno Y, Koyama H, Matsumoto K, Onishi Y, Takenaka D, Fujisawa Y, et al. Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT. Radiology. 2011;258:599–609.PubMedCrossRef
18.
Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245–52.PubMedCrossRef
19.
Huang T, Civelek AC, Li J, Jiang H, Ng CK, Postel GC, et al. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med. 2012;53:1262–8.PubMedCrossRef
20.
Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med. 2007;48:1761–6.PubMedCrossRef
21.
Miles KA, Hayball M, Dixon AK. Colour perfusion imaging: a new application of computed tomography. Lancet. 1991;337:643–5.PubMedCrossRef
22.
Tacelli N, Remy-Jardin M, Copin MC, Scherpereel A, Mensier E, Jaillard S, et al. Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology. 2010;257:863–71.PubMedCrossRef
23.
van den Hoff J. Assessment of lung cancer perfusion by using patlak analysis: what do we measure? Radiology. 2007;243:907–8.PubMedCrossRef
24.
Thieme SF, Johnson TR, Lee C, McWilliams J, Becker CR, Reiser MF, et al. Dual-energy CT for the assessment of contrast material distribution in the pulmonary parenchyma. AJR Am J Roentgenol. 2009;193:144–9.PubMedCrossRef
25.
Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, et al. Quantitative analysis of response to treatment with Erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2011;52:1871–7.PubMedCrossRef
26.
Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology. 2011;261:598–604.PubMedCrossRef
27.
Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–76.PubMedCrossRef
Metadata
Title
Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer
Authors
Alexander W. Sauter
Daniel Spira
Maximilian Schulze
Christina Pfannenberg
Jürgen Hetzel
Matthias Reimold
Ernst Klotz
Claus D. Claussen
Marius S. Horger
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2318-2

Other articles of this Issue 5/2013

European Journal of Nuclear Medicine and Molecular Imaging 5/2013 Go to the issue

Guidelines

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

Erratum

Erratum to: Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates

Editorial

Multiple opportunities to reduce radiation dose from myocardial perfusion imaging

Image of the Month

Sensitivity of PET/MRI to detect recurrence of prostate cancer

Review Article

When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Original Article

Performance evaluation of small-animal multipinhole μSPECT scanners for mouse imaging